Parathyroid Hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

Journal of Bone and Mineral Research

Volumn 25, Issue 2, 2010, Pages 178-189

  Kramer, Ina ^a   Loots, Gabriela G ^b,c   Studer, Anne ^a   Keller, Hansjoerg ^a   Kneissel, Michaela ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetic mouse models; Osteocytes; Osteoporosis; PTH; SOST

Indexed keywords

PARATHYROID HORMONE[1-34]; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; PARATHYROID HORMONE; SOST PROTEIN, HUMAN;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; BONE MINERAL; COMPUTER ASSISTED TOMOGRAPHY; CONTENT ANALYSIS; CONTROLLED STUDY; DIAPHYSIS; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EX VIVO STUDY; FEMUR; FOLLOW UP; GENE DELETION; GENE OVEREXPRESSION; GENE REPRESSION; IN VIVO STUDY; LOW DRUG DOSE; LUMBAR SPINE; MALE; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MUTATION; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; POLYMERASE CHAIN REACTION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TIBIA; TREATMENT DURATION; WILD TYPE; ANIMAL; DRUG EFFECTS; GENETIC MARKER; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PARATHYROID HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77952992328     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090730     Document Type: Article

References (50)

1. Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006;8:28-39.
2. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688-703.
3. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008;118:421-428. (Pubitemid 351206529)
4. Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991;254:1024-1026. (Pubitemid 21917436)
5. Nishida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994;15:717-723. (Pubitemid 24332666)
6. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 2008;42:806-818.
7. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995;136:3632-3638.
8. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-446. (Pubitemid 29534328)
9. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278:50259-50272. (Pubitemid 37548867)
10. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-1446.
11. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158. (Pubitemid 40962421)
12. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577-4583. (Pubitemid 41446595)
13. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008;3:e2942.
14. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci. 2007;1116:281-290.
15. Fermor B, Skerry TM. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res. 1995;10:1935-1943.
16. Langub MC, Monier-Faugere MC, Qi Q, Geng Z, Koszewski NJ, Malluche HH. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res. 2001;16:448-456. (Pubitemid 32173359)
17. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16:319-327.
18. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842-1844. (Pubitemid 41598769)
19. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-6276.
20. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15:928-935. (Pubitemid 40994212)
21. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869. (Pubitemid 351768804)
22. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543. (Pubitemid 32184286)
23. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589. (Pubitemid 32202753)
24. Balemans W, Patel N, Ebeling M, et al. Identification of a 52-kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97. (Pubitemid 34146376)
25. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144-152.
26. Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analogue SDZ PTS 893 or human PTH(1-34). Bone. 2001;28:237-250.
27. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
28. Marshall VM, Allison J, Templeton T, Foote SJ. Generation of BAC transgenic mice. Methods Mol Biol. 2004;256:159-182.
29. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007;38:261-269. (Pubitemid 47106897)
30. Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007;22:1957-1967. (Pubitemid 351229312)
31. Zhou H, Iida-Klein A, Lu SS, et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone. 2003;32:513-520. (Pubitemid 39665710)
32. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001;16:1575-1582. (Pubitemid 32786425)
33. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004;35:828-835. (Pubitemid 39349213)
34. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22:19-28. (Pubitemid 46032593)
35. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996;18:397-403.
36. Poole KE, Reeve J. Parathyroid hormone: a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005;5:612-617. (Pubitemid 41614461)
37. Potts JT, Gardella TJ. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann NY Acad Sci. 2007;1117:196-208.
38. Li X, Zhang Y, Kang H, Liu W, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-19887. (Pubitemid 41379516)
39. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770-26775. (Pubitemid 41040710)
40. Baron R, Rawadi G. Targeting the Wnt/b-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643. (Pubitemid 46984775)
41. Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007;148:2630-2634.
42. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007;19:376-382. (Pubitemid 46884195)
43. Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys. 2008;473:112-116.
44. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006;281:23698-23711. (Pubitemid 44274145)
45. Iwaniec UT, Wronski TJ, Liu J, et al. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res. 2007;22:394-402. (Pubitemid 46797122)
46. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007;210:352-357. (Pubitemid 44956880)
47. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005;95:1178-1190. (Pubitemid 41420125)
48. Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006;147:2583-2590.
49. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3β in osteoblastic Saos-2 cells. J Cell Biochem. 2008;104:304-317.
50. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008;22:2968-2679.